相似文献
1
Octanoic acid suppresses harmaline-induced tremor in mouse model of essential tremor.
Neurotherapeutics. 2012 Jul;9(3):635-8. doi: 10.1007/s13311-012-0121-1.
2
Carbenoxolone and mefloquine suppress tremor in the harmaline mouse model of essential tremor.
Mov Disord. 2006 Oct;21(10):1641-9. doi: 10.1002/mds.20940.
3
Harmaline-induced tremor as a potential preclinical screening method for essential tremor medications.
Mov Disord. 2005 Mar;20(3):298-305. doi: 10.1002/mds.20331.
4
Agmatine has beneficial effect on harmaline-induced essential tremor in rat.
Neurosci Lett. 2021 May 14;753:135881. doi: 10.1016/j.neulet.2021.135881. Epub 2021 Apr 7.
5
An open-label, single-dose, crossover study of the pharmacokinetics and metabolism of two oral formulations of 1-octanol in patients with essential tremor.
Neurotherapeutics. 2011 Oct;8(4):753-62. doi: 10.1007/s13311-011-0045-1.
6
T-type calcium channel antagonists suppress tremor in two mouse models of essential tremor.
Neuropharmacology. 2010 Nov;59(6):380-7. doi: 10.1016/j.neuropharm.2010.05.012. Epub 2010 Jun 12.
7
Effects of unilateral stereotactic posterior striatotomy on harmaline-induced tremor in rats.
J Neurosci Res. 2013 Oct;91(10):1328-37. doi: 10.1002/jnr.23249. Epub 2013 Jul 19.
8
A Role for GABA Receptor β3 Subunits in Mediating Harmaline Tremor Suppression by Alcohol: Implications for Essential Tremor Therapy.
Tremor Other Hyperkinet Mov (N Y). 2024 Apr 26;14:20. doi: 10.5334/tohm.834. eCollection 2024.
9
Modulation of sphingosine-1-phosphate receptor ameliorates harmaline-induced essential tremor in rat.
Neurosci Lett. 2017 Jul 13;653:376-381. doi: 10.1016/j.neulet.2017.06.015. Epub 2017 Jun 13.
10
Phytohormone abscisic acid elicits positive effects on harmaline-induced cognitive and motor disturbances in a rat model of essential tremor.
Brain Behav. 2022 May;12(5):e2564. doi: 10.1002/brb3.2564. Epub 2022 Apr 5.
引用本文的文献
1
Identification of Potential Lead Compounds Targeting Novel Druggable Cavity of SARS-CoV-2 Spike Trimer by Molecular Dynamics Simulations.
Int J Mol Sci. 2023 Mar 27;24(7):6281. doi: 10.3390/ijms24076281.
2
Genome Estimation and Phytochemical Compound Identification in the Leaves and Callus of : A Locally Endangered Plant from the Flora of Saudi Arabia.
Plants (Basel). 2022 Feb 21;11(4):567. doi: 10.3390/plants11040567.
3
Mechanisms and Pharmacotherapy for Ethanol-Responsive Movement Disorders.
Front Neurol. 2020 Aug 25;11:892. doi: 10.3389/fneur.2020.00892. eCollection 2020.
4
Managing Essential Tremor.
Neurotherapeutics. 2020 Oct;17(4):1603-1621. doi: 10.1007/s13311-020-00899-2.
5
Current and Future Neuropharmacological Options for the Treatment of Essential Tremor.
Curr Neuropharmacol. 2020;18(6):518-537. doi: 10.2174/1570159X18666200124145743.
6
Review on clinical update of essential tremor.
Neurol Sci. 2016 Apr;37(4):495-502. doi: 10.1007/s10072-015-2380-1. Epub 2016 Jan 9.
7
Treatment of essential tremor with long-chain alcohols: still experimental or ready for prime time?
Tremor Other Hyperkinet Mov (N Y). 2014 Feb 5;4. doi: 10.7916/D8RX991R. eCollection 2014.
8
Octanoic acid in alcohol-responsive essential tremor: a randomized controlled study.
Neurology. 2013 Mar 5;80(10):933-40. doi: 10.1212/WNL.0b013e3182840c4f. Epub 2013 Feb 13.
本文引用的文献
1
Defective dentate nucleus GABA receptors in essential tremor.
Brain. 2012 Jan;135(Pt 1):105-16. doi: 10.1093/brain/awr301. Epub 2011 Nov 26.
2
Evidence-based guideline update: treatment of essential tremor: report of the Quality Standards subcommittee of the American Academy of Neurology.
Neurology. 2011 Nov 8;77(19):1752-5. doi: 10.1212/WNL.0b013e318236f0fd. Epub 2011 Oct 19.
3
Validation of digital spiral analysis as outcome parameter for clinical trials in essential tremor.
Mov Disord. 2011 Sep;26(11):2073-80. doi: 10.1002/mds.23808. Epub 2011 Jun 28.
4
Milestones in tremor research.
Mov Disord. 2011 May;26(6):1096-105. doi: 10.1002/mds.23579.
5
An open-label, single-dose, crossover study of the pharmacokinetics and metabolism of two oral formulations of 1-octanol in patients with essential tremor.
Neurotherapeutics. 2011 Oct;8(4):753-62. doi: 10.1007/s13311-011-0045-1.
6
Treatment of patients with essential tremor.
Lancet Neurol. 2011 Feb;10(2):148-61. doi: 10.1016/S1474-4422(10)70322-7.
7
GABAergic dysfunction in essential tremor: an 11C-flumazenil PET study.
J Nucl Med. 2010 Jul;51(7):1030-5. doi: 10.2967/jnumed.109.074120. Epub 2010 Jun 16.
8
Harmaline-induced tremor as a potential preclinical screening method for essential tremor medications.
Mov Disord. 2005 Mar;20(3):298-305. doi: 10.1002/mds.20331.
9
Open-label dose-escalation study of oral 1-octanol in patients with essential tremor.
Neurology. 2004 Jun 22;62(12):2320-2. doi: 10.1212/wnl.62.12.2320.
10
Pilot trial of 1-octanol in essential tremor.
Neurology. 2004 Jan 13;62(1):122-4. doi: 10.1212/01.wnl.0000101722.95137.19.
Zotero 插件